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Breast cancer is an important disease worldwide, primarily affecting women, and is the most 
common and deadliest form of female cancer. This is reflected in New Zealand’s population as 
breast cancer has high incidence and mortality rates. In New Zealand, almost 700 deaths occur 
each year due to breast cancer, with a majority due to metastases.  
The progression of cancer into a metastatic disease requires a change in cell phenotype, possibly 
through a process called epithelial-to-mesenchymal transition (EMT). When EMT occurs, fully 
epithelial cells, with cell to cell junctions and apical-basolateral polarity, transition into cells with 
a mesenchymal phenotype, becoming more invasive and motile and changing their morphology. 
Ion channels are reported to be important regulators of EMT including some evidence for a role 
of the epithelial sodium channel (ENaC). ENaC mRNA expression has been correlated with 
prognosis in breast cancer patients. Aldosterone, which increases ENaC mRNA and protein in 
other tissue, has been shown to alter breast cancer cell migration. This suggests that ENaC may 
have a role in breast cancer cell migration. 
The aims of this project were to understand the role of α-ENaC and δ-ENaC in breast cancer cell 
migration by increasing and decreasing their expression within the cells. My hypotheses were 
“overexpression of α-ENaC or δ-ENaC will cause an increase in breast cancer cell migration” and 
“knockdown of α-ENaC or δ-ENaC will cause a decrease in breast cancer cell migration”.  
Two breast cancer cell lines, BT-549 and MDA-MB-231, were used in this project to model breast 
cancer cell migration. These cells were transfected to either overexpress or knockdown α-ENaC 
or δ-ENaC. Scratch assays were then performed to quantify any changes in migration speed of 
the cells. The cells were then lysed and underwent qPCR to validate the overexpression or 
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knockdown. To compare the role of ENaC in breast cancer cell migration, a two-way ANOVA was 
performed.  
Overexpression or knockdown of α-ENaC in MDA-MB-231 and BT-549 cells did not significantly 
alter migration of the cells compared to control cells. Results from qPCR analysis showed 
successful overexpression of α-ENaC. Similarly, overexpression or knockdown of δ-ENaC in MDA-
MB-231 and BT-549 cells did not significantly alter migration of the cells. Results from the qPCR 
showed overexpression of δ-ENaC in both cell lines was successful. Results from qPCR 
experiments have shown that attempts to knockdown of α-ENaC and δ-ENaC were unsuccessful 
in both cell lines. 
The results did not support the hypothesis that altering levels of α-ENaC or δ-ENaC would change 
the rate of breast cancer cell migration, although a second migration assay should be used to 
confirm these results. Therefore, ENaC may be regulating another pathway, such as proliferation, 
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1.1 Breast Cancer 
1.1.1 Epidemiology 
Breast cancer in an important disease worldwide with it being the most common and deadliest 
form of cancer in females (Bray et al., 2018). GloboCan 2018, produced by the International 
Agency for Research on Cancer, estimated that almost a quarter of new female cancer and 
15% of female cancer deaths were due to breast cancer. They also found that the 
Australia/New Zealand region had the highest age-standardised rate of breast cancer at 94.2 
cases per 100,000 females (Bray et al., 2018). This is supported by figures from the Ministry of 
Health that show a high burden in New Zealand population, especially on the Māori 
population. In 2017, an age standardised incidence rate of 130 cases per 100,000 females was 
reported for Māori and 90 cases per 100,000 females for non-Māori (Ministry of Health, 2019). 
This trend is also seen in mortality data from 2016 with an age standardised mortality rate of 
21.8 deaths per 100,000 females for Māori compared to 16.8 deaths per 100,000 females for 
non-Māori (Ministry of Health, 2018). Approximately 700 women in New Zealand die each year 
due to breast cancer, with the majority of breast cancer deaths due to metastases (Jin & Mu, 
2015; Ministry of Health, 2018). 
1.1.2 Classification 
Breast cancer is a heterogeneous disease and can be classified in different ways. These include 
histological grade and subtype, stage of disease, and molecular subtype. These different 
classifications can predict the prognosis of the patients with different treatment strategies 
employed for different classifications.   
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Breast cancer can be classified based on the appearance of biopsied cells into a histological 
subtype and grade. Histological subtype refers to classification of breast cancer cells based 
upon the different morphological and cytological features of the cell and how they may impact 
the disease (Weigelt et al., 2010). The World Health Organisation reports many different 
subtypes with most common being “Invasive breast carcinoma, no special type” which 
accounts for approximately 55% of all breast cancer (Makki, 2015). This subtype includes all 
breast carcinoma that do not have enough features to justify classification of a special type. 
Special types of breast carcinoma make up 25% of all breast cancer with common subtypes 
including invasive lobular carcinoma, medullary carcinoma, and invasive cribriform carcinoma 
(Weigelt et al., 2010; Sinn & Kreipe, 2013). Another important histologically identified subtype 
is ductal carcinoma in situ (DCIS). DCIS is a pre-cancerous growth that can develop into invasive 
carcinomas (Sinn & Kreipe, 2013; Makki, 2015). The histological grade of breast cancer can 
also be determined based on appearance. This is based on tubule formation, nuclear 
pleomorphism, and mitotic count (Elston & Ellis, 1991). Breast cancer grade can be classified 
as I, for well differentiated, II, for moderately differentiated, and III, for poorly differentiated 
with grade III having the worst prognosis (Elston & Ellis, 1991). 
Breast cancer can also be classified based on the stage of disease. Tumour Node Metastasis 
(TNM) staging is based on three factors: size of the primary tumour (T), number of regional 
lymph nodes affected (N), and whether metastases has occurred (M) (Giuliano et al., 2017). 
There are four stages I, II, III, and IV with stage IV having the worst prognosis. Tumour size 
ranges from T0, with no evidence of a primary tumour, to T4, where the tumour causes a direct 
extension of the chest wall or skin. The number of regional axillary lymph nodes affected 
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determines the classification of N0 to N3, with the classification escalating as the number of 
affected lymph nodes increases. This denotes the cells from the primary tumour that are able 
to migrate into the axillary lymph nodes. If the cells are able to travel further and seed in 
different organs, this is referred to as metastases, leading to a classification of M1 rather than 
M0 for no metastases. Different combinations of these lead to staging with metastases being 
a requirement for a stage IV classification (Giuliano et al., 2017).  
The molecular subtypes of breast cancer are based on the expression of different markers that 
affect prognosis. The markers include oestrogen and progesterone hormone receptor status, 
human epidermal growth factor receptor 2 (HER-2) status, and the level of Ki67 proliferation 
marker. There are five molecular subtypes which include Luminal A, Luminal B HER-2 negative, 
Luminal B HER-2 positive, HER-2 positive, and Basal-like or Triple Negative (Table 1.1) 
(Goldhirsch et al., 2011). Each of these have different prognoses and treatment strategies 
based on the expression of the molecular targets. Luminal A breast cancer has the highest 5-





Table 1.1: Breast Cancer subtype characteristics, prevalence, and 5-year all causes survival 
(1: Goldhirsch et al., 2011; 2: Lawrenson et al., 2018) 
Subtype [1] Characteristics [1] Prevalence [2] 5-year 
Survival [2] 
Luminal A Oestrogen and/or Progesterone Positive 
HER-2 Negative 





Oestrogen and/or Progesterone Positive 
HER-2 Negative 
High Ki-67  
12.2% 81.6% 
Luminal B  
HER-2 
Positive 


















1.1.3 Risk Factors and Treatments 
Interventions to reduce the occurrence of breast cancer require an understanding of the risk 
factors associated with the development of breast cancer. These risk factors include age, 
lifestyle factors, reproductive factors, and genetics. Age is an important risk factor in the 
development of breast cancer as older women are at a higher risk of developing breast cancer. 
In New Zealand, a majority of new breast cancer diagnoses in 2016 occurred in women over 
the age of 45 (Ministry of Health, 2019). Lifestyle factors such as low physical activity, high 
body mass index (BMI), poor diet, and high alcohol consumption all increase the risk of 
developing breast cancer (Rojas & Stuckey, 2016). The reproductive factors of a women are 
also important predictors of breast cancer development. Early age of menarche, older age at 
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first child birth, low parity, and later age of menopause all contribute to increased risk of 
developing breast cancer (Horn et al., 2013). Genetics can also influence the risk of developing 
breast cancer, with breast cancer susceptibility gene type 1 and 2 (BRCA1/2) as a well-known 
example. BRCA1 is located on chromosome 17q21, and BRCA2 is located on chromosome 
13q12. These are anti-tumour genes and so mutations lead to an increased risk of breast 
cancer (Sun et al., 2017). The cumulative risk of developing breast cancer by age 70 was 57% 
for BRCA1 carriers and 49% for BRCA2 carriers (Chen & Parmigiani, 2007).   
While some of these risk factors can be modified to lower risk of developing breast cancer, 
others cannot so these women may be at higher risk of developing breast cancer and should 
be closely monitored. This could be accomplished through breast cancer screening initiatives 
such as BreastScreen Aotearoa (BSA). BSA is a breast cancer screening programme in New 
Zealand that offers a free mammogram every two years to women aged 45 to 69 years. This 
enables early detection of breast cancer, leading to a better prognosis. Screen detected 
cancers were more likely to be small, localised, low grade, and less advanced tumours when 
to non-screen detected tumours (Ministry of Health, 2015; Seneviratne et al., 2016). An 
evaluation of BSA revealed that it was responsible for a 34% decrease in mortality between 
screened and non-screened women, between the years of 1999 to 2011 (Ministry of Health, 
2015). Increasing accessibility to screening will allow for increased detection of early stage 
breast cancers to which effective treatments are available. Screen detection of advanced and 
metastatic breast cancers would likely have little effect on prognosis due to ineffective 
treatments. Therefore, more research is required to develop efficacious therapies to reduce 
deaths caused by advanced breast cancers.  
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The current treatments for breast cancer vary with breast cancer subtype. Surgery to remove 
the primary tumour is usually the first step in breast cancer treatment either by mastectomy, 
where all the breast tissue is removed, or more commonly breast conserving surgery, where 
only the affected regions are removed (Matsen & Neumayer, 2013). Axillary lymph nodes may 
be removed based on whether the sentinel node or the first axillary lymph node, contain 
cancer cells. If the sentinel node is clear of cancer cells, no more axillary lymph nodes are 
required to be removed (Matsen & Neumayer, 2013; Davies, 2016). Other treatments include 
Radiation therapy, Chemotherapy, Hormone therapy, and other targeted treatments including 
trastuzumab. Radiation therapy is a targeted therapy that involves administering beams of 
radiation to affected regions after surgery to kill any remaining tumour cells (Breast Cancer 
Foundation NZ, 2019). Another treatment option is chemotherapy which is a systemic 
treatment. Chemotherapy targets fast proliferating cells such as cancer cells and can be 
administered before surgery to reduce the size of the primary tumour, or after surgery to kill 
any remaining tumour cells that may have escaped surgical removal (Breast Cancer Foundation 
NZ, 2019). Anthracyclines and Taxanes are the standard chemotherapy treatments, 
administered over a four to six month period (Davies, 2016; Breast Cancer Foundation NZ, 
2019). Hormone therapy is another therapeutic option that can be used against breast cancer 
subtypes expressing the oestrogen or progesterone hormone receptors. These subtypes 
receive growth signals from oestrogen and progesterone circulating in the body. Hormone 
therapy works by blocking these signals and slowing tumour growth. Tamoxifen and 
aromatase inhibitors are examples of hormone therapies (Davies, 2016; Breast Cancer 
Foundation NZ, 2019). Breast cancer subtypes expressing the HER-2 receptor can be treated 
7 
 
with trastuzumab, an anti-HER-2 monoclonal antibody. This binds to the receptor, stopping it 
from binding its targets and receiving growth signals (Harbeck & Gnant, 2017; Breast Cancer 
Foundation NZ, 2019).  
1.1.4 Metastasis 
Metastases occur when cells from the primary tumour are able to escape and seed within 
distant organs. With metastatic breast cancer, this usually occurs within the brain, bones, and 
lungs (Jin & Mu, 2015). Metastatic breast cancer is currently considered an incurable disease 
consequently resulting in a majority of breast cancer deaths. Current treatments are not very 
effective as metastatic breast cancer has a 5-year survival rate of only 26% (Li & Kang, 2016). 
Systemic treatments including chemotherapy, hormone therapy, and anti-HER-2 trastuzumab 
are currently being used depending on whether the subtype of the tumour expresses the 
targets. There are currently few effective treatments targeting metastases directly, therefore 
further research into pathways involved in cancer progression, such as how primary breast 
cancer cells acquire the ability to migrate to other areas of the body, is required. This 
progression may occur through a process called epithelial to mesenchymal transition (EMT).  
1.2 Epithelial to Mesenchymal Transition (EMT) 
1.2.1 EMT Process, Markers, Regulators 
Epithelial to Mesenchymal Transition (EMT) is a process where fully differentiated epithelial 
cells transition into cells with a more mesenchymal phenotype. Epithelial cells lose cell-to-cell 
junctions and apical-basolateral polarity and gain mesenchymal characteristics including 
becoming more invasive and motile with a spindle-like morphology (Figure 1.1) (Zhang & 
Weinberg, 2018). EMT is a reversible process, with a spectrum of intermediate phenotypes 
available depending on the EMT transcription factors expressed as well as the tissue 
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environment (Zhang & Weinberg, 2018; Pastushenko & Blanpain, 2019). It was initially 
described as a developmental process and is now relevant in the context of cancer (Campbell, 
2018).  
EMT is a complex process with many intermediate transition states possible. This allows for 
speculation concerning the different roles these transition states may play in cancer 
progression. This means it could be possible for one transition state to be responsible for 
migration, another for invasion, another for proliferation and so on (Pastushenko & Blanpain, 
2019). The state of transition that a cell is in is widely described based on the markers 
expressed by the cell. Markers of EMT include E-Cadherin as an epithelial marker and N-
Cadherin and Vimentin as mesenchymal markers (Campbell, 2018). EMT transcription factors 
which include Snail, Slug, Twist, ZEB1, and ZEB2 can also be used as a marker to confirm 
whether EMT is occurring (Garg, 2013).  
 
Figure 1.1 Original figure showing a phenotypic change with Epithelial to Mesenchymal 
Transition. The epithelial state has cell to cell junctions with apical-basolateral polarity. 
Epithelial state expresses E-Cadherin marker and higher ENaC mRNA. The mesenchymal state 
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has a spindle-like morphology with higher invasive and motile abilities. Mesenchymal state 
expresses Vimentin and N-Cadherin markers and lower ENaC mRNA. 
1.2.2 Metastatic Cascade 
For cancer to progress into metastases, the metastatic cascade must occur. This involves local 
invasion of surrounding tissue, intravasion into blood or lymphatic vessels, survival within the 
circulation, extravasion into a distant organ, survival in the new environment, and outgrowth 
within the new tissue (Valastyan & Weinberg, 2011; Jin & Mu, 2015). For these steps to occur, 
the cells must change phenotype and adopt characteristics that allow for this progression. 
Using EMT pathways, these cells can lose their cell to cell junctions and become more 
migratory and invasive (Jin & Mu, 2015). When arriving at the distant organ, the reverse 
process, Mesenchymal to Epithelial transition (MET), may occur to help seed the cell in the 
new environment (Wang & Zhou, 2011).  The role of EMT in the progression of cancer is 
important and so understanding what regulates EMT, for instance ion channels, may help 
reduce the development of metastases.  
1.2.3 Ion Channels and EMT 
Ion channels have been shown to regulate EMT. Ion channels such as the human Ether-à-go-
go-related gene 1 (hERG1), Cystic Fibrosis transmembrane conductance regulator (CFTR), and 
Transient receptor potential-melastatin-like 7 (TRMP7), have been shown to be involved in 
EMT (Zhang et al., 2013; Davis et al., 2014; Fortunato, 2017). A role of potassium channel, 
hERG1, in EMT was demonstrated by Fortunato (Fortunato, 2017). When hERG1 was silenced 
in mesenchymal HCT116 colorectal carcinoma cells, the morphology and proliferative ability 
was altered. The cells transitioned to become more flat with less membrane protrusions and 
became less proliferative. The expression of several EMT markers was quantified and showed 
that the hERG1 silenced cells had a more epithelial profile compared to the non-silenced cells 
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(Fortunato, 2017). The chloride and bicarbonate channel, CFTR, was also shown to be involved 
in EMT (Zhang et al., 2013). When EMT was induced in MCF-7 epithelial breast cancer cells, a 
decrease in expression of CFTR and epithelial marker E-Cadherin was observed, with an 
increase in the cell’s ability to migrate and invade. When CFTR was overexpressed in MDA-MB-
231 mesenchymal breast cancer cells, , invasion and migration were repressed with an 
increase in the epithelial marker, E-Cadherin, and a decrease in the mesenchymal marker, 
Vimentin (Zhang et al., 2013). Calcium channel, TRMP7, may also be involved in EMT (Davis et 
al., 2014). TRMP7 plays an important role in mediating an intracellular calcium signal that was 
necessary for EMT to occur. When TRMP7 was knocked down, there was a reduction of the 
mesenchymal marker Vimentin that leads to a more epithelial phenotype (Davis et al., 2014).  
In addition to this, preliminary data from the McDonald laboratory has suggested a role for 
another ion channel, the epithelial sodium channel (ENaC), in EMT. The expression of α-ENaC, 
β-ENaC, and γ-ENaC mRNA was compared between pre-EMT epithelial breast cancer cell lines 
and post-EMT mesenchymal breast cancer cell lines. They found that α-ENaC, β-ENaC, and γ-
ENaC mRNA expression was higher in the pre-EMT epithelial cell lines compared to the post-
EMT mesenchymal cell lines (Figure 1.1) (Ware, Cunliffe, and McDonald, unpublished data). 
This suggests a potential role of ENaC in regulating EMT.  
1.3 ENaC 
ENaC is a sodium channel and belongs to the ENaC/Degenerin family (Hanukoglu & Hanukoglu, 
2016). It is found on many epithelia including kidney, lung, colon, and mammary epithelia 
among others (Boyd & Náray-Fejes-Tóth, 2007; Hanukoglu & Hanukoglu, 2016). It is a 
heterotrimer composed of an α-subunit or δ-subunit, a β-subunit, and a γ-subunit (Figure 1.2). 
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These subunits are encoded by SCNN1A, SCNN1D, SCNN1B, and SCNN1G respectively. Each 
subunit consists of two transmembrane domains, a large extracellular loop, and intracellular 
N- and C-termini (Hanukoglu & Hanukoglu, 2016). The structure of ENaC was recently resolved 
using cryo-electron microscopy revealing a heterotrimer arranged in a counter-clockwise 
manner. Each subunit was described as resembling a hand holding a ball, with palm, knuckle, 
finger, thumb, and ball domains (Noreng et al., 2018). An interaction between the subunits 
was observed between the finger domain and the knuckle domain of the adjacent subunit. The 
pore of the channel is made up of the second transmembrane domain of each subunit. The 
binding site of amiloride, which inhibits ENaC function, and the G/SxS selectivity filter, which 
allows for high specificity for sodium ions over potassium ions, are found in close proximity to 
this pore (Kellenberger & Schild, 2002; Noreng et al., 2018).   
 
Figure 1.2: Original figure ENaC Structure with an α- or δ-ENaC subunit, a β-ENaC subunit, 
and a γ-ENaC subunit. Each subunit consists of two transmembrane domains with a large 
extracellular loop and intracellular terminal domains. Not to scale. 
1.3.1 ENaC and Blood Pressure Regulation 
An important role of ENaC is in blood pressure regulation. Sodium ions are an important 
electrolyte involved in extracellular fluid volume. ENaC is found on epithelia of the distal 
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nephron where it reabsorbs sodium ions, creating an osmotic gradient for water to follow. This 
process can be regulated by aldosterone. Aldosterone is a mineralocorticoid hormone 
produced within the adrenal gland (Booth et al., 2002). It has a well characterised role in 
responding to low blood pressure conditions as part of the Renin-Angiotensin-Aldosterone-
System (RAAS) pathway (Booth et al., 2002). Aldosterone binds to the mineralocorticoid 
receptor (MR) within the principal cells of the cortical collecting duct of the kidney nephron. A 
rapid response, mediated by the serum and glucocorticoid-regulated kinase 1 (SGK1), 
increases ENaC activity and ENaC trafficking to the cell surface, and decreases ENaC 
endocytosis (Loffing et al., 2001; Hermidorff et al., 2017; Valinsky et al., 2018) A later genomic 
response increases synthesis of ENaC (Verrey, 1995). These result in increased sodium ion 
reabsorption which provides an osmotic gradient for water reabsorption leading to the 
expansion of blood volume, and thus an increase in blood pressure back to normal (Hanukoglu 
& Hanukoglu, 2016; Valinsky et al., 2018). Mutations in the sequence of ENaC lead to 
dysregulation of blood pressure, resulting in diseases such as Liddle syndrome and 
Pseudohypoaldosteronism Type 1 (PHA1) (Hanukoglu & Hanukoglu, 2016). Liddle syndrome is 
characterised by early onset hypertension, hypokalaemia, metabolic alkalosis, low levels of 
renin and aldosterone. This is caused by a gain of function mutation which leads to an increase 
in sodium reabsorption (Shimkets, 1994). PHA1 is characterised by salt wasting, 
hyperkalaemia, and metabolic acidosis. This is caused by a loss of function mutation resulting 




The δ-ENaC subunit is encoded by the SCNN1D gene. It is a subunit that is found in humans 
but not within rodent models and therefore cannot be easily studied. It can replace α-ENaC to 
form a heterotrimer with β-ENaC and γ-ENaC. The δ-ENaC subunit can be found on both 
epithelial and non-epithelial tissue, with expression in heart, liver, brain, lung, skeletal muscle, 
and blood leukocytes compared to αβγ-ENaC, which is predominantly expressed in the 
kidneys, lungs and liver (Ji et al., 2012). Compared to αβγ-ENaC, δβγ-ENaC shows higher 
selectivity for sodium ions over lithium ions, is more sensitive to extracellular protons, and less 
sensitive to inhibition by amiloride (Giraldez et al., 2012; Ji et al., 2012). The function of δ-
ENaC is still unknown with some suggestion of roles within the brain, pancreas, and lung 
(Giraldez et al., 2012). 
1.3.3 ENaC and Migration 
ENaC has been shown to be involved in cellular migration. A study investigated the role of 
ENaC in migration of keratinocytes (Yang et al., 2013). They demonstrated that ENaC 
influences the direction of movement in the presence of an electric field that exist within a 
wound. ENaC is able to stabilise lamellipodia in the direction of the cathode and leads to 
directional migration to close the wound (Yang et al., 2013). ENaC has also been shown to be 
involved in vascular smooth muscle cell (VSMC) migration (Grifoni et al., 2006). ENaC was 
confirmed to be expressed within two VSMC cell lines, SV40-LT and A10 (Grifoni et al., 2006). 
The migratory ability of these cells were significantly reduced when ENaC was inhibited by 
benzamil, or knocked down with siRNA (Grifoni et al., 2006). This suggests that ENaC plays an 
important role in VSMC migration. 
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The role of ENaC in migration could be explained by its contribution to cell volume as well as 
its interaction with the cell cytoskeleton. ENaC may be involved in regulatory volume increase 
(RVI). When cells are put under hypertonic stress, hypertonicity-induced cation channels are 
induced to restore cell volume. When ENaC subunits were knocked down in rat hepatocytes, 
these cells had a reduced RVI response. This suggests that ENaC may be related to these 
hypertonicity-induced cation channels (Plettenberg et al., 2008). ENaC has also been shown to 
have direct interactions with the cellular cytoskeleton (Mazzochi et al., 2006).  A co-
sedimentation assay was performed and showed a direct interaction between the C-terminal 
domain of α-ENaC and F-actin (Mazzochi et al., 2006). These show ENaC is involved in cell 
migration. This is possibly due to its role in cell volume or its interaction with the cell 
cytoskeleton, leading to the formation of cellular protrusions required for cellular migration 
(Schwab, 2001). 
1.3.4 ENaC and Cancer 
A number of studies have shown a role for ENaC in cancer (Kapoor et al., 2009; del Mónaco et 
al., 2009; Yamamura et al., 2008; Amara et al., 2016). Due to their location on the cell surface, 
ion channels such as ENaC are accessible targets for potential treatments of cancer 
(Prevarskaya et al., 2018). ENaC and acid sensing ion channel 1 (ASIC1), members of the 
ENaC/Degenerin superfamily, have been shown to be involved in migration of D54-MG human 
glioblastoma multiforme cells (Kapoor et al., 2009). D54-MG cells had significantly higher 
mRNA expression of ASIC1, α-ENaC, and γ-ENaC compared to primary human astrocytes. 
When these subunits were knocked down, they observed a reduction in migration compared 
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to the control. Treatment of these cells with an amiloride analogue, benzamil, also lead to a 
reduction in migration (Kapoor et al., 2009).  
Another study looked at the role of ENaC in choriocarcinoma. A study by del Monaco et al, 
investigated the change in migration of BeWo choriocarcinoma cancer cells using a wound 
healing assay with aldosterone to increase ENaC activity, and amiloride to inhibit ENaC activity. 
They observed a significant increase in cell migration when aldosterone was added as 
compared to the control. Using sense and anti-sense oligonucleotides for α-ENaC, they 
demonstrated that the increase in migration with aldosterone was due to ENaC. They showed 
that cells with anti-sense oligonucleotides had decreased migration compared to cells with 
sense oligonucleotides and no oligonucleotides (del Mónaco et al., 2009). This showed that 
ENaC has a role in migration in choriocarcinoma cells (del Mónaco et al., 2009). 
Another study looking at G-361 melanoma cells suggested the involvement of ENaC in cancer 
(Yamamura et al., 2008). They demonstrated that all four ENaC subunits were expressed 
within the G-361 melanoma cells using reverse transcription polymerase chain reaction (RT-
PCR), in-situ hybridisation, and immunostaining. Validating the expression of ENaC within 
these melanoma cells suggests a potential role as a novel target in the treatment of melanoma 
(Yamamura et al., 2008). 
However, there is limited research looking at ENaC in breast cancer. One study suggests ENaC 
is involved with IL-17 and inflammatory stress in breast cancer cells that aid in tumour 
proliferation (Amara et al., 2016). High sodium chloride and IL-17 in breast cancer cell lines 
leads to production of reactive oxygen and nitrogen species. There was increased expression 
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of the γ-ENaC subunit when the cell was treated with both IL-17 and high sodium chloride. 
Knock down of γ-ENaC also led to a reduction in the production of reactive oxygen and 
nitrogen species suggesting that it is involved (Amara et al., 2016). This study shows that ENaC 
is involved in breast cancer. 
A bioinformatics tool, created by Györffy et al, is able to compare the effect of expression 
levels of genes on breast cancer prognosis (Györffy et al., 2010). Using this bioinformatics tool, 
SCNN1A and SCNN1D, or α-ENaC and δ-ENaC, were examined (Figure 1.3) and the results 
showed that higher expression of either α-ENaC or δ-ENaC mRNA in breast cancer patients 
was correlated with a better prognosis. This also suggests a role of ENaC in breast cancer.  
  
Figure 1.3: Higher expression of α-ENaC or δ-ENaC was correlated with a better prognosis. 
Carried out by author using bioinformatics tool developed by Györffy et al. The red line 
represents the prognosis with high expression of the gene of interest and the black line 
represents the prognosis with low expression of the gene of interest. Left) Comparison of high 
and low α-ENaC expression with Breast Cancer survival; Right) Comparison of high and low 
expression of δ-ENaC with Breast Cancer survival. 
1.4 Project Rationale 
Breast cancer is an important disease around the world. Almost 700 deaths occur each year in 
New Zealand, with a majority of breast cancer deaths due to metastases. Current treatments 
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for metastatic breast cancer are limited so identifying novel targets could potentially reduce 
the burden of disease. EMT has been shown to be important in cancer progression into a 
metastatic disease, with ion channels being identified as important regulators of EMT. 
Preliminary data from the McDonald laboratory suggests that ENaC may be involved in EMT, 
as ENaC mRNA levels is higher in epithelial-like breast cancer cell lines compared to 
mesenchymal-like breast cancer cell lines. While ENaC plays a vital role in blood pressure 
regulation, a role of ENaC in cell migration has also been shown. ENaC has also been 
demonstrated to be involved in many different cancers including glioblastoma, 
choriocarcinoma, melanoma, and breast cancer, with bioinformatics data suggesting that 
higher expression of ENaC mRNA improves the prognosis of breast cancer patients. A previous 
honours student from the McDonald Laboratory explored the role of ENaC in breast cancer 
cell migration with the use of aldosterone to upregulate ENaC expression, and amiloride to 
inhibit ENaC function. Scratch assays and Boyden Chamber assays were conducted to observe 
whether migration was affected by the different conditions. McQueen (2018), found that 
amiloride could significantly reduce migration in scratch assays in two breast cancer cell lines, 
while aldosterone was able to increase migration in one breast cancer cell line but reduced 
migration in another (McQueen, 2018). This shows that ENaC may be involved in breast cancer 
cell migration, but more specific up and down regulation of ENaC is required to build on these 
results.  
1.5 Aims and Hypothesis 
The aim of this project was to understand the role of ENaC, specifically α-ENaC and δ-ENaC, in 
breast cancer cell migration. To do this α-ENaC or δ-ENaC were overexpressed or knocked 
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down within two breast cancer cell lines. Scratch assays were performed as a functional test 
for breast cancer cell migration and qPCR was performed to validate whether successful 
transfection has occurred.  
My hypotheses were that: 
“Overexpression of α-ENaC or δ-ENaC in mesenchymal breast cancer cells would lead to an 
increase in migration” 
and 
“Knockdown of α-ENaC or δ-ENaC in mesenchymal breast cancer cells would lead to a decrease 
in migration”.  
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2 Methods and Materials 
2.1 Cells 
For this project, two triple negative mesenchymal breast cancer cell lines: MDA-MB-231 and 
BT-549 cells were obtained from Dr Heather Cunliffe (Department of Pathology, University of 
Otago). Cell stocks were grown on 6cm cell culture plates (Falcon, Cat. No. 353002, Corning, 
USA) and incubated at 37˚C with 5.5% CO2 in a Forma Series II incubator (Thermo Electron 
Corporation). All experiments were performed in Physical Containment 2 laboratories. 
2.1.1 MDA-MB-231  
MDA-MB-231 cells are a triple negative, mesenchymal breast cancer cell line originating from 
the pleural effusion of a Caucasian female (Figure 2.1A). These cells were grown in filtered 
(Corning, Cat. No. COR430513, USA) RPMI-1640 media (Gibco, Cat. No. 31800-022, Thermo 
Fisher Scientific, USA) supplemented with 2g/L of glucose, 1.5g/L of sodium bicarbonate, 10% 
Foetal Bovine serum (FBS) (Gibco, Cat. No. 10091-155, Thermo Fisher Scientific, USA), and 1% 
penicillin streptomycin (Gibco, Cat. No. 15140-122, Thermo Fisher Scientific, USA). 
2.1.2 BT-549 
BT-549 cells are another triple negative, mesenchymal breast cancer cell line originating from 
the mammary gland of a Caucasian female (Figure 2.1B). These cells were grown in filtered 
RPMI-1640 media supplemented with 4.5g/L of glucose, 1.5g/L of sodium bicarbonate, 
110.04mg/L of sodium pyruvate, 2383mg/L of HEPES, 800 μL/L of insulin-transferrin-selenium 










Figure 2.1: Images of the two cell lines used in this project. A) MDA-MB-231 Cells; B) BT-549 
Cells. Viewed under 20x magnification using an Olympus CKX41 microscope. 
2.2 Cell Passaging  
MDA-MB-231 and BT-549 cells were passaged twice a week to ensure healthy growth of the 
cells and to limit cell death due to overcrowding. This was carried out in a sterile biological 
safety cabinet (Class II Type A2, Labconco) to minimise the chance of infection of the cells. The 
cell media was removed using a vacuum with a sterile pipette tip attached. The cells were 
subsequently washed using filtered phosphate-buffered saline (PBS) (Gibco, Cat. No. 18912-
014, Thermo Fisher Scientific, USA) to remove any dead cells. The PBS was then removed and 
~500μL of 0.25% Trypsin/ 1mM EDTA (Gibco, Cat. No. 25200-056, Thermo Fisher Scientific, 
USA) was pipetted onto the plate. The plate was incubated for ~5 minutes, then 1mL of cell 
specific media was added to neutralise the trypsin and the cells were resuspended by gentle 
pipetting. From here the cells can be counted (Section 2.3) or directly seeded onto a new plate. 
A new 6cm cell culture plate had 4mL of cell media pipetted onto it and ~400μL of media 
containing approximately 400,000 resuspended cells was pipetted drop-wise around the plate. 
The plate was then labelled with my name, date, cell line, and passage number, with the 
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passage number increasing by one from the previous plate. This was placed into the 37˚C + 
5.5% CO2 incubator until confluence was reached again in approximately 3 days. 
2.3 Cell Counting 
Similar steps to cell passaging (Section 2.2) were performed to lift the cells off the plate. The 
cell containing solution was transferred into a 15mL tube (Greiner Bio-One, Cat. No. 188261, 
Greiner, Germany) and centrifuged (Eppendorf, Centrifuge 5702) for 3 minutes at 3 
revolutions per minute (RPM). The cell media was then removed and the cell pellet was 
resuspended in 1mL of media. A volume of 10μL was pipetted onto a haemocytometer 
(Marienfeld, Cat. No. 0680010, Germany) and the number of cells within a 5X5 grid was 
counted (n) using the 10X objective on a microscope (Olympus, CKX41). This gives a 
concentration of cells at nx104/mL. The solution with the known number of cells can then be 
used to seed a specific number of cells onto a plate using the c1v1 = c2v2 formula.  
2.4 Scratch Assay 
The scratch assay or wound healing assay was performed to quantify the ability of a cell to 
migrate (Hulkower & Herber, 2011). A scratch was made on a monolayer of cells where nearby 
cells can infiltrate. Photographs were taken at specific time points to observe changes in the 
size of the scratch area due to migration. This was conducted over a 24h period therefore the 
decrease in scratch area was likely due to cellular migration rather than proliferation. Each 
condition was repeated until at least four biological repeats (N), using cells with different 
passage numbers, and four total experimental repeats (n) was reached. 
2.4.1 Cell Seeding 
Cells were counted following the method from the cell counting section (Section 2.3). A 
volume containing 300,000 cells was calculated and pipetted drop-wise onto one well of a six-
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well plate (Greiner Bio-One, Cat. No. GRE657160, Greiner, Germany) containing 2mL of media. 
This was repeated for the five remaining wells. These wells were left for approximately one 
day to form a confluent monolayer, at which point transfection could occur. Each cell line was 
put into separate rows of the six-well plate, with each column having a different experimental 
condition (Figure 2.2). 
 
Figure 2.2: Experimental set-up for the Scratch Assays using a six-well plate. Each row 
contains the same cell-line e.g. MDA-MB-231 in row A and BT-549 in row B. Each column 
contains the same condition e.g. Control in column 1, α-ENaC overexpression in column 2, and 
δ-ENaC overexpression in column 3. 
2.4.2 Cell Transfection 
Cell transfection is a technique that allows the uptake of genetic material into cells. This was 
performed to understand the role of specific proteins by modifying their expression and 
observing the resultant phenotype. In this project, transfection was achieved using the 





Cells seeded onto a plate were left for one day to adhere to the plate and form a confluent 
monolayer. Two micro-centrifuge tubes (Multi-Max, Cat. No. MUL2942, USA) were required 
for each transfection. The first micro-centrifuge tube was filled with 50μL of serum-free media 
and 3μL of Lipofectamine 3000 and incubated for ~5 minutes. The second micro-centrifuge 
tube was filled with 50μL of serum-free media, 2μL of P3000, and 0.3μg of DNA plasmid, for 
overexpression experiments, or 20pmol of siRNA, for knockdown experiments, and were 
vortex mixed. The solution within the second micro-centrifuge tube was transferred to the 
first micro-centrifuge tube and vortex mixed. This was incubated for ~15 minutes at room 
temperature to enable formation of liposome complexes. The media, within the six well plate 
containing cells, was replaced with serum-free media and the transfection solution was added 
to the plate in a drop-wise fashion evenly around the plate. After six hours, the media was 
replaced with serum containing media.  
2.4.2.1 DNA Plasmid 
The DNA plasmids used for overexpression in this project utilised the pMT3 vector which 
contains an adenovirus major late promoter (Swick et al., 1992). This project used human α-
ENaC and δ-ENaC with pMT3 vector and an empty pMT3 vector as the control. Approximately 
0.3μg of DNA plasmid was transfected per experiment.  
2.4.2.2 siRNA 
siRNAs were used to bind to their complementary mRNA, and inhibit translation leading to 
decreasing protein level. For this project α-ENaC siRNA and δ-ENaC siRNA (Sigma Aldrich, USA) 
(Table 2.1) were used to knockdown α-ENaC and δ-ENaC respectively, with scrambled mouse 
control siRNA (Dharmacon, Horizon Discovery, USA) used as the control. Approximately 
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20pmol of siRNA was transfected per experiment. The siRNA complementary binding site can 
be predicted using the Basic Local Alignment Search Tool (BLAST) 
Table 2.1: siRNAs used in this project with their sequence, complementary target sequence 
position, and manufacturer. 
siRNA Sequence siRNA Target Position 
α-ENaC GCT CTT TGA CCT GTA CAA A 912bp – 930bp; Exon 
δ-ENaC CAA GTC AGC TGG ATG GAC T 2134bp – 2152bp; Exon 
2.4.2.3 Aldosterone 
A previous honours project demonstrated that aldosterone was able to alter migration in 
MDA-MB-231 and BT-549 mesenchymal breast cancer cells (McQueen, 2018). An aldosterone 
scratch assay was performed as a positive control alongside an α-ENaC overexpression and 
control scratch assays. The scratch assays were set up as previously described (Section 2.4.1 
and 2.4.2.). The control cells and aldosterone cells were transfected with pMT3 empty vector 
control, while the α-ENaC overexpression cells were transfected with α-ENaC DNA plasmids. 
The cell monolayers were then scratched and the cell media was replaced to remove any 
debris (Section 2.4.3). A volume of aldosterone, resulting in a concentration of 10nM, was 
pipetted drop-wise to the aldosterone well.  The same volume of 100% ethanol pipetted drop-
wise to the control and α-ENaC wells as a vehicle control. 
2.4.3 Scratching Protocol 
A glass pipette with a rounded tip was used to scratch the cell monolayer. The glass pipette 
was sterilised by dipping into 100% ethanol and flaming with a lighter. This was carried out 
twice before scratching each plate. Light pressure was used to remove the cells off the plate, 
but not enough to damage the plate. The plate lid was used as a guide for the scratch to be 
made. An initial vertical scratch was made followed by a second horizontal scratch (Figure 2.3) 
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and a point of reference was added using a permanent marker where the scratches intersect. 
The plate was then washed with 1mL of PBS to remove any floating or dead cells and full media 
was added.  
 
Figure 2.3: Depicts changes to the cell monolayer following scratching of plate and cell 
migration. A) Monolayer before the Scratch; B) Scratch at 0 hours; C) Scratch at 12 hours. Black 
rectangles represent the area captured in the photograph. 
2.4.4 Photograph 
Photographs of the scratch area were taken with a microscope with the 10X objective 
(Olympus U-RFLT50) using an Infinity 3-1UM microscope camera and Infinity Capture software 
(Teledyne Lumenera, Canada). The photographs were taken at seven time points: 0, 1, 3, 5, 8, 
12, and 24 hours after the scratch. Two photographs were taken of each plate, at each time 
point, capturing the same scratch area relative to the reference point (Figure 2.4). The 
photographs captured were analysed using Image J (Version 1.52n, NIH, USA) with an MRI 
Wound Healing Tool Macro (Montpellier RIO Imaging, CNRS, Montpellier, France). The options 
were set to Method: Variance, 10 for “Variance Filter Radius”, 40 for “Threshold”, 6 for “Radius 
Open”, and 10000 for “Minimum Size”. The photographs were first processed in Image J by 
first smoothing the image, followed by enhancing contrast by 0.3%. The scratch area of the 




Figure 2.4: Two photographs were captured at each time point for each plate. The black 
rectangles represent the area captured for analysis by the photographs. 
2.4.5 Cell Lysis 
After the last photograph was taken at 24 hours after the scratch, the cells were lysed and the 
lysate was collected for quantitative polymerase chain reaction (qPCR). The media was 
removed and the plate was washed with PBS. To lyse the cells, 300μL of TRIzol reagent 
(Invitrogen, Cat. No. 15596026, Thermo Fisher Scientific, USA) was added to the plate, and 
incubated for ~5 minutes. The cell lysates were collected and transferred to micro-centrifuge 
tubes. These were labelled and stored in a -80˚C freezer until it was ready for RNA extraction. 
2.5 RNA Extraction 
RNA extraction was performed using the “RNeasy Micro Kit” (Qiagen, Cat. No. 74004, 
Germany) following the “TGen BOCRU RNA Micro Prep Extraction w/Qiagen RNeasy Kit” 
protocol by C. Mancini (Section 6.1). Cell lysates were thawed and 40μL of chloroform added. 
This separated the cell lysates into an upper aqueous layer containing RNA, and a lower organic 
layer containing DNA and proteins. The aqueous layer was collected and underwent a series 
of washing and centrifugation steps using the Qiagen Micro-RNeasy Column. This resulted in 
20μL of extracted RNA and the concentration of this RNA was quantified using a microplate 
reader (BioTek, Synergy 2). 
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2.6 Reverse Transcription  
Complementary or Template DNA (cDNA) was required for PCR and was synthesised by 
performing reverse transcription with extracted RNA (Section 2.5). This was carried out using 
the “PrimeScript RT Reagent Kit” (Takara, Cat. No. RR037A, Japan). Reverse transcription was 
performed by adding to a micro-centrifuge tube: 2μL of 5x Primescript buffer, 0.5μL of reverse 
transcriptase enzyme, 0.5μL of Oligo dT primer, 0.5μL of random hexamers, extracted RNA, 
and water to a total of 10μL. Each reaction required RNA at a final concentration of 50ng/μL 
which was calculated using the known RNA concentration. This was incubated at 37˚C for 15 
minutes. The reverse transcriptase enzyme was then inactivated by incubating samples at 85˚C 
for 5 seconds and 40μL of water was added to dilute the cDNA 5x, resulting in 50μL of cDNA 
that was ready for qPCR. 
2.7 Quantitative Polymerase Chain Reaction 
Quantitative polymerase chain reaction (qPCR) was conducted to determine whether 
transfection of plasmid DNA or siRNA was successful. This was performed on a 96-well plate 
(Multi-Max, Cat. No. MUL3890, USA) with each experimental condition carried out in triplicate 
per gene of interest and then the plate was sealed (Excel Scientific, Cat. No. EXCTS-RT2RR-100, 
USA). Each well contained 10μL of solution consisting of 5μL of SYBR with ROX (Takara, Cat. 
No. RR420L, Japan), 3.6μL of water, 0.2μL of forward primer, 0.2μL of reverse primer, and 1μL 
of cDNA.  
2.7.1 Primers 
The primers used in my experiment were: α-ENaC, δ-ENaC, and GAPDH (Sigma Aldrich, USA) 
(Table 2.2). The PCR product sizes were predicted using BLAST (National Center for 
Biotechnological Information, 2019). 
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Table 2.2: Primers used in this project with their sequence, manufacturer, and the predicted 
PCR product size. 
Primer Sequence PCR Product Size 
GAPDH Forward Primer  ACAGTTGCCATGTAGACC  
88bp GAPDH Reverse Primer TTGAGCACAGGGTACTTTA 
α-ENaC Forward Primer GGGTACTGCTACTATAAGCTC  
185bp α-ENaC Reverse Primer TTGACGGTGTAATTGTTCTG 
δ-ENaC Forward Primer AGGGAGTCTGCATTCAAG  
143bp δ-ENaC Reverse Primer GATGTTGATTTTGGCCAGG 
 
2.7.2 Cycle  
The qPCR cycle protocol was designed by Dr Adam Ware from the McDonald Lab and was 
conducted using Bio-Rad’s CFX Connect Real-Time System. The steps of the protocol are as 
outlined in Table 2.3. 
Table 2.3: Steps with corresponding action featuring temperature and time 
Step Action 
1 95˚C for 10 minutes 
2 95˚C for 15 seconds 
3 60˚C for 1 minute 
4 Repeat Steps 2-3 40 times 
5 65˚C for 15 seconds 
6 95˚C for 30 seconds 
 
2.7.3 Fold Change Calculation  
To determine the magnitude of the change in mRNA expression with overexpression and 
knockdown, a fold change calculation was carried out using the 2-ΔΔCT equation. This calculated 
the fold change relative to the experimental control, normalised with the GAPDH 
housekeeping gene, using the difference in PCR cycle times. 
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2.7.4 Agarose Gel Electrophoresis 
To determine whether the primers produced the correct PCR product, agarose gel 
electrophoresis was performed. Agarose gel electrophoresis can approximate the size of PCR 
products, based on the position of the band on the gel relative to a ladder after completion. A 
2.5% agarose gel was made by combining 1.5g of agarose (Bioline, Cat. No. BIO-41025, United 
Kingdom) with 60mL of 1x TAE Buffer. This was microwaved until it boiled and the solution 
became transparent. This was left to cool for ~5 minutes at which point 5μL of SYBR safe DNA 
gel stain (Invitrogen, Cat. No. S33102, Thermo Fisher Scientific, USA) was added. The solution 
was then carefully poured into a gel mould and left to set for ~15 minutes. During this time, 
the PCR products were prepared. Experimental and water control triplicates were chosen and 
the triplicates were pooled together with 2μL of gel loading dye (New England Biolabs, Cat. 
No. B7025S, USA). The experimental triplicate contained cDNA and primers while the water 
control triplicate contained water and primers. In an empty well 2μL of gel loading dye was 
mixed with 0.7μL of the ladder solution (New England Biolabs, Cat. No. N3200S, USA). When 
the gel had set, it was placed into the running chamber (Bio-Rad, Wide Mini-Sub Cell GT Cell) 
and submerged in 1x TAE buffer, with the gel oriented so the wells were closest to the negative 
electrode. The wells were loaded with the ladder loaded into the leftmost well followed by 
each pair of experimental and water control triplicates. The agarose gel electrophoresis was 
run at a constant voltage of 100V, 3A, and 300W for 30 minutes (Select BioProducts, BioVolt 
250V). Once this was complete, the gel could be imaged (Syngene, PXi). The size of the PCR 
products could be estimated using its position relative to the ladder. This could be compared 
with the predicted size of the PCR products. 
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2.8 Statistical Analysis 
2.8.1 Two-way ANOVA 
A two-way ANOVA with Tukey’s post hoc test was performed to identify any statistically 
significant differences in the cell migration from the scratch assays. This was carried out using 
Prism 7 and identified whether there was a difference in the means of each condition at each 
time point. A P-value of less than 0.05 was considered a statistically significant difference.  
2.8.2 Student’s T-Test 
Unpaired Student’s T-Tests with Welch’s correction for unequal variance were performed to 
identify whether there was a significant difference in the mean relative fold change of α-ENaC 
mRNA or δ-ENaC mRNA, when these were overexpressed or knocked down, compared to the 
control. This was carried out using Prism 7 to determine whether overexpression with plasmid 
DNA transfection, or knockdown with siRNA transfection, was successful. A P-value of less than 





This project aimed to understand the role of α-ENaC and δ-ENaC in breast cancer cell 
migration. To do this, α-ENaC or δ-ENaC were either overexpressed or knocked down in two 
mesenchymal breast cancer cell lines: MDA-MB-231 and BT-549. The migratory ability of these 
cells was assessed with the use of scratch assays. Photographs were taken of the scratch area 
at seven time points: 0, 1, 3, 5, 8, 12, and 24 hours after the scratch. As the cells migrate into 
the scratch area, the area that remained uncovered by cells at each time point decreased. The 
uncovered area at each time point was quantified, using the MRI wound healing macro on 
Image J, as a percentage of the original scratch area. These experiments were repeated until 
each experimental condition achieved at least four biological (N) repeats, with cells of different 
passage numbers, and four total experimental (n) repeats. The area at each time point was 
averaged and the results were plotted on a graph with time in hours on the X axis and scratch 
area as a percentage of the original scratch area on the Y axis. The cells were then lysed and 
qPCR was performed to validate whether transfection was successful. These results were 
represented as the fold change relative to the control. My hypotheses were that 
overexpression of α-ENaC or δ-ENaC will cause an increase in migration of mesenchymal 
breast cancer cells and knockdown of α-ENaC or δ-ENaC will cause a decrease in migration of 




3.1 Effect of altering α-ENaC and δ-ENaC in MDA-MB-231 cells 
3.1.1 MDA-MB-231 α-ENaC and δ-ENaC Overexpression 
The role of ENaC in breast cancer cell migration was initially investigated in MDA-MB-231 
mesenchymal breast cancer cells. MDA-MB-231 cells were transfected with DNA plasmids to 
overexpress either α-ENaC or δ-ENaC, or with a control plasmid with cell migration being 
compared using scratch assays (Figure 3.1). At 12 hours post-scratch, the mean percentage of 
the scratch area uncovered by cells for the control was 30.9%, 30.0% for α-ENaC 
overexpression, and 35.4% for δ-ENaC overexpression (Figure 3.1B, D, F). A two-way ANOVA 
with Tukey’s post hoc test was performed and reported no statistically significant differences 
between α-ENaC overexpression and control, or δ-ENaC overexpression and control at any 
time point. This suggests that overexpression of α-ENaC or δ-ENaC in MDA-MB-231 cells had 
no effect on cell migration (N=8; n=12) (Figure 3.1G) thus contradicting the hypothesis that 
overexpression of α-ENaC or δ-ENaC will cause an increase in migration of mesenchymal 

































Figure 3.1: The migration of MDA-MB-231 cells, in scratch assays, showed no difference 
when either α-ENaC or δ-ENaC was overexpressed, compared to the control. A) Control 
scratch area at time of scratch (0 hours); B) Control scratch area at 12 hours after the scratch 
(12 Hours); C) α-ENaC overexpression scratch area at time of scratch (0 hours); D) α-ENaC 
overexpression scratch area at 12 hours after the scratch; E) δ-ENaC overexpression scratch 
area at time of scratch (0 hours); F) δ-ENaC overexpression scratch area at 12 hours after 
scratch; G) Pooled results comparing the migratory ability of MDA-MB-231 cells with α-ENaC 
overexpression and δ-ENaC overexpression to control. Mean ±SEM. Analysed using a two-way 
ANOVA with Tukey’s post hoc test. No statistically significant differences were observed 




To determine whether this was due to unsuccessful transfection of plasmids encoding either 
α-ENaC or δ-ENaC, qPCR was performed using RNA extracted from cells used in the scratch 
assays described above. The qPCR results showed the mean fold change of α-ENaC mRNA 
when α-ENaC was overexpressed, was approximately a 13-fold increase relative to the control 
(N=5) (Figure 3.2A). This was not a statistically significant difference when analysed using an 
unpaired t-test with Welch’s correction (P=0.10). This was trending toward statistical 
significance and was likely due to the large variation in the size of the fold change as every 
experiment had an increase of at least 4-fold relative to the control. When δ-ENaC was 
overexpressed, an approximately 4-fold mean increase in δ-ENaC mRNA was shown relative 
to the control (N=5) (Figure 3.2B). There was a statistically significant difference compared to 
the control (P=0.03), when analysed using an unpaired t-test with Welch’s correction. 
Therefore, overexpression of α-ENaC or δ-ENaC in MDA-MB-231 cells was successful. This 
suggests that overexpression of α-ENaC or δ-ENaC does not influence migration of MDA-MB-
231 breast cancer cells. 
To confirm whether the primers were producing the correct PCR product, agarose gel 
electrophoresis was performed. GAPDH, α-ENaC, and δ-ENaC primers were used in this project 
and were run alongside a water control. Using the basic local alignment search tool (BLAST), 
the size of the product was predicted and compared with the position of the band relative to 
the ladder. The PCR product size of GAPDH was 88bp, 185bp for α-ENaC, and 143bp for δ-
ENaC. The DNA gel showed a single band at the correct position and so the primers correctly 





Figure 3.2: Overexpression of α-ENaC or δ-ENaC in MDA-MB-231 cells. A) α-ENaC 
overexpression had an approximately 13-fold mean increase in α-ENaC mRNA relative to the 
control. Mean ±SEM. This was trending toward a statistically significant difference when 
analysed using an unpaired t-test with Welch’s correction. P=0.10, N=5, n=9. B) δ-ENaC 
overexpression had an approximately 4-fold mean increase in δ-ENaC mRNA relative to the 
control. This was found to be statistically significant when analysed using an unpaired t-test 
with Welch’s correction. *P=0.03, N=5, n=9. 
 
 A B C D E F G  
 
Figure 3.3: Agarose gel electrophoresis confirmed the amplification. A) Ladder; B) GAPDH 
PCR product; C) GAPDH water control; D) α-ENaC PCR Product; E) α-ENaC water control; F) δ-






3.1.2 MDA-MB-231 α-ENaC and δ-ENaC Knockdown 
As the overexpression of α-ENaC or δ-ENaC does not influence the migration of MDA-MB-231 
cells, the role of ENaC in breast cancer cell migration was investigated further by observing the 
effect of lowering α-ENaC and δ-ENaC expression. MDA-MB-231 cells were transfected with 
siRNA to knockdown either α-ENaC, δ-ENaC, or with a control siRNA. Cell migration was 
compared using scratch assays (Figure 3.4). At 12 hours post-scratch, the mean percentage of 
the scratch area unfilled for the control was 33.5%, 37.2% for α-ENaC knockdown, and 43.4% 
for δ-ENaC knockdown (Figure 3.4B, D, F). A two-way ANOVA with Tukey’s post hoc test was 
performed and this reported no statistically significant differences between α-ENaC 
knockdown and control or δ-ENaC knockdown and control at any time point (N=5; n=5) (Figure 
3.4G). Therefore, knockdown of α-ENaC or δ-ENaC in MDA-MB-231 cells had no effect on cell 
migration. This contradicted the hypothesis that knockdown of α-ENaC and δ-ENaC will cause 
a decrease in migration of mesenchymal breast cancer cells. 
To validate whether transfection of siRNAs was successful, qPCR was performed using RNA 
extracted from cells used in the scratch assays described above. When α-ENaC was knocked 
down, there was an approximate 1.5-fold increase in α-ENaC mRNA relative to the control 
(N=3) (Figure 3.5A). This was not a statistically significant difference (P=0.42), when analysed 
using an unpaired t-test with Welch’s correction. When δ-ENaC was knocked down, an 
approximate 1.1-fold decrease in δ-ENaC mRNA was shown relative to the control (N=3) 
(Figure 3.5B). There was not a statistically significant difference compared to the control 
(P=0.44) when analysed using an unpaired t-test with Welch’s correction, suggesting that the 
37 
 
knockdown of α-ENaC and δ-ENaC in MDA-MD-231 cells was unsuccessful. This could explain 
why no effect in migration was observed in these cells when conducting scratch assays.   
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Figure 3.4: The migration of MDA-MB-231 cells, in scratch assays, showed no difference 
when α-ENaC or δ-ENaC was knocked down, compared to the control. A) Control scratch area 
at time of scratch (0 Hour); B) Control scratch area at 12 hours after the scratch (12 Hours); C) 
α-ENaC knockdown scratch area at time of scratch (0 Hour); D) α-ENaC knockdown scratch 
area at 12 hours after the scratch (12 Hours); E) δ-ENaC knockdown scratch area at time of 
scratch (0 Hour); F) δ-ENaC knockdown scratch area at 12 hours after scratch (12 Hours); G) 
Pooled results comparing the migratory ability of MDA-MD-231 cells with α-ENaC knockdown 
and δ-ENaC knockdown to control. Mean ±SEM. Analysed using a two-way ANOVA with 
Tukey’s post hoc test. No statistically significant differences were observed between α-ENaC 





Figure 3.5: Knockdown of α-ENaC or δ-ENaC in MDA-MB-231 cells. A) α-ENaC knockdown had 
an approximately 1.5-fold mean increase in α-ENaC mRNA relative to the control. Mean ±SEM. 
This was not a statistically significant difference when analysed using an unpaired t-test with 
Welch’s correction. P=0.42, N=3, n=3. B) δ-ENaC knockdown had an approximately 1.1-fold 
mean decrease in δ-ENaC mRNA relative to the control. This was not statistically significant 




3.2 Effect of altering α-ENaC and δ-ENaC in BT-549 cells 
3.2.1 BT-549 α-ENaC and δ-ENaC Overexpression 
The role of ENaC in breast cancer cell migration was then investigated in another mesenchymal 
breast cancer cell line, BT-549. BT-549 cells were transfected with DNA plasmids to 
overexpress either α-ENaC, δ-ENaC, or with control plasmid and cell migration was compared 
using scratch assays (Figure 3.6). At 12 hours post-scratch, the mean percentage of the scratch 
area unfilled for the control was 35.8%, 39.7% for α-ENaC overexpression, and 39.8% for δ-
ENaC overexpression (Figure 3.6B, D, F). A two-way ANOVA with Tukey’s post hoc test was 
performed and this reported no statistically significant differences at any time points between 
α-ENaC overexpression and control or δ-ENaC overexpression and control (N=4; n=6) (Figure 
3.6G). Therefore, overexpression of α-ENaC or δ-ENaC in BT-549 cells had no effect on cell 
migration. This contradicted the hypothesis that overexpression of α-ENaC and δ-ENaC will 
cause an increase in migration of mesenchymal breast cancer cells. 
qPCR was performed to validate whether successful transfection had occurred using RNA 
extracted from cells used in the scratch assays described above. This revealed the mean fold 
change of α-ENaC, when α-ENaC was overexpressed, was approximately 700-fold increase 
relative to the control (N=4) (Figure 3.7A). This was a statistically significant difference 
(P=0.03), when analysed using an unpaired t-test with Welch’s correction. When δ-ENaC was 
overexpressed, an approximate 8-fold increase in δ-ENaC mRNA was observed relative to the 
control (N=4) (Figure 3.7B). This was a statistically significant difference compared to the 
control (P=0.002), when analysed using an unpaired t-test with Welch’s correction. 
Overexpression of α-ENaC or δ-ENaC in BT-549 cells was successful suggesting that α-ENaC or 
δ-ENaC are not involved in BT-549 cell migration.  
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Figure 3.6: The migration of BT-549 cells, in scratch assays, showed no difference when α-
ENaC or δ-ENaC was overexpressed, compared to the control. A) Control scratch area at time 
of scratch (0 Hour); B) Control scratch area at 12 hours after the scratch (12 Hours); C) α-ENaC 
overexpression scratch area at time of scratch (0 Hour); D) α-ENaC overexpression scratch area 
at 12 hours after the scratch (12 Hours); E) δ-ENaC overexpression scratch area at time of 
scratch (0 Hour); F) δ-ENaC overexpression scratch area at 12 hours after scratch (12 Hours); 
G) Pooled results comparing the migratory ability of BT-549 cells with α-ENaC overexpression 
and δ-ENaC overexpression to control. Mean ±SEM. Analysed using a two-way ANOVA with 
Tukey’s post hoc test. No statistically significant differences were observed between α-ENaC 





Figure 3.7: Overexpression of α-ENaC or δ-ENaC in BT-549 cells. A) α-ENaC overexpression 
had an approximately 700-fold mean increase in α-ENaC mRNA relative to the control. Mean 
±SEM. This was a statistically significant difference when analysed using an unpaired t-test 
with Welch’s correction. *P=0.03, N=4, n=6. B) δ-ENaC overexpression had an approximately 
8-fold mean increase in δ-ENaC mRNA relative to the control. This was found to be statistically 





3.2.2 BT-549 α-ENaC and δ-ENaC Knockdown 
The effect of lowering expression of α-ENaC and δ-ENaC on cell migration was also explored 
in BT-549 mesenchymal breast cancer cells. BT-549 cells were transfected with siRNA to 
knockdown either α-ENaC, δ-ENaC, or with a control siRNA. Cell migration was compared using 
scratch assays (Figure 3.8). At 12 hours the mean percentage of the scratch area unfilled for 
the control was 42.9%, 39.7% for α-ENaC knockdown, and 55.5% for δ-ENaC knockdown 
(Figure 3.8B, D, F). A two-way ANOVA with Tukey’s post hoc test was performed and reported 
no statistically significant differences between α-ENaC knockdown and control or δ-ENaC 
knockdown and control at any time points (N=4; n=4) (Figure 3.8G). Therefore, knockdown of 
α-ENaC or δ-ENaC in BT-549 cells had no effect on cell migration. This contradicted the 
hypothesis that knockdown of α-ENaC and δ-ENaC will cause a decrease in migration of 
mesenchymal breast cancer cells. Interestingly a statistically significant difference in migration 
was observed between α-ENaC knockdown and δ-ENaC knockdown at 12 and 24 hours after 
the scratch (P=0.02; P=0.04 respectively) suggesting δ-ENaC may have a role in breast cancer 
cell migration. 
qPCR was performed to validate if transfection was successful using RNA extracted from cells 
used in the scratch assays described above. When α-ENaC was knocked down, an unexpected 
approximate mean fold change of 1.7-fold increase was observed in α-ENaC mRNA relative to 
the control (N=3) (Figure 3.9A). This was not a statistically significant difference (P=0.29), when 
analysed using an unpaired t-test with Welch’s correction. Again, when δ-ENaC was knocked 
down, an unexpected approximate 1.4-fold mean increase in δ-ENaC mRNA was shown 
relative to the control (N=3) (Figure 3.9B). There was no statistically significant difference 
44 
 
compared to the control (P=0.14) when analysed using an unpaired t-test with Welch’s 
correction. Knockdown of α-ENaC and δ-ENaC in BT-549 cells was unsuccessful.  
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Figure 3.8: The migration of BT-549 cells, in scratch assays, showed no difference when α-
ENaC or δ-ENaC was knocked down, compared to the control. A) Control scratch area at time 
of scratch (0 Hour); B) Control scratch area at 12 hours after the scratch (12 Hours); C) α-ENaC 
knockdown scratch area at time of scratch; D) α-ENaC knockdown scratch area at 12 hours 
after the scratch; E) δ-ENaC knockdown scratch area at time of scratch; F) δ-ENaC knockdown 
scratch area at 12 hours after scratch; G) Pooled results comparing the migratory ability of BT-
549 cells with α-ENaC knockdown and δ-ENaC knockdown to control. Mean ±SEM. Analysed 
using a two-way ANOVA with Tukey’s post hoc test. No statistically significant differences were 
observed between α-ENaC knockdown and control or δ-ENaC knockdown and control. N=4, 
n=4. *: Significant difference between cell migration of α-ENaC knockdown and δ-ENaC 





Figure 3.9: Knockdown of α-ENaC or δ-ENaC in BT-549 cells. A) α-ENaC knockdown had an 
approximately 1.7-fold mean increase in α-ENaC mRNA relative to the control. Mean ±SEM. 
This was not a statistically significant difference when analysed using an unpaired t-test with 
Welch’s correction. P=0.2954, N=3, n=3. B) δ-ENaC knockdown had an approximately 1.4-fold 
mean increase in δ-ENaC mRNA relative to the control. This was not statistically significant 




3.3 Aldosterone and α-ENaC Overexpression 
This project aimed to build upon the results of a previous honours student’s project which also 
investigated the role of ENaC in breast cancer cell migration (McQueen, 2018). In the previous 
project, pharmacological agents: amiloride and aldosterone were used. Amiloride was used to 
inhibit ENaC activity, with concentrations of 2nM and 10nM. Aldosterone was used to increase 
ENaC expression using concentrations of 5nM and 10nM. The use of 10nM of aldosterone was 
observed to significantly increase migration in BT-549 cells but significantly reduce migration 
in MDA-MB-231 cells. The results of the project described in this thesis observed no effect on 
cell migration with either overexpression or knockdown of α-ENaC or δ-ENaC in the two 
mesenchymal breast cancer cell lines utilised. Therefore a 10nM aldosterone scratch assay 
was performed alongside an α-ENaC overexpression scratch assay to act as a positive control.  
3.3.1 MDA-MB-231 Aldosterone and α-ENaC Overexpression 
To compare the effect of aldosterone (10nM) and α-ENaC overexpression on breast cancer cell 
migration, scratch assays were performed utilising MDA-MB-231 cells. At 12 hours post-
scratch, the mean percentage of the scratch area unfilled for the control was 44.7%, 38.5% for 
α-ENaC overexpression, and 39.8% for aldosterone (10nM) (Figure 3.10B, D, F). A two-way 
ANOVA with Tukey’s post hoc test was performed and reported no statistically significant 
differences at any time points between α-ENaC overexpression and control or aldosterone 
(10nM) and control (N=6; n=6) (Figure 3.10G). The results observed in the previous honours 
project could not be replicated.  
3.3.2 BT-549 Cells Aldosterone and α-ENaC Overexpression 
These experiments were performed in another mesenchymal breast cancer cell line, BT-549 
cells, to compare with the results observed in MDA-MB-231 cells. At 12 hours post-scratch, 
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the mean percentage of the scratch area unfilled for the control was 69.2%, 63.6% for α-ENaC 
overexpression and 69.9% for aldosterone (10nM) (Figure 3.11B, D, F). A two-way ANOVA with 
Tukey’s post hoc test was performed and reported no statistically significant differences at any 
time points between α-ENaC overexpression and control or δ-ENaC overexpression and 
control (N=5; n=5) (Figure 3.11G). The results observed in the previous honours project could 
not be replicated.  
Due to time constraints, qPCR was not performed. As α-ENaC overexpression was successful 
in previous experiments utilising the same protocol, it was assumed that overexpression was 
successful in these experiments. The functional status of the aldosterone used in these 
experiment was tested after obtaining the results, to determine whether it was able to 
increase ENaC activity. An Ussing chamber current measurement experiment was performed 
and the aldosterone used in this experiment was not able to increase ENaC current compared 
to the control, as previously observed when treating with aldosterone.  This suggests that this 

































Figure 3.10: The migration of MDA-MB-231 cells, in scratch assays, showed no difference 
with α-ENaC overexpression or 10nM aldosterone, compared to the control. A) Control 
scratch area at time of scratch (0 Hour); B) Control scratch area at 12 hours after the scratch 
(12 Hours); C) α-ENaC overexpression scratch area at time of scratch (0 Hour); D) α-ENaC 
overexpression scratch area at 12 hours after the scratch (12 Hours); E) Aldosterone (10nM) 
scratch area at time of scratch (0 Hour); F) Aldosterone (10nM) scratch area at 12 hours after 
scratch (12 Hours); G) Pooled results comparing the migratory ability of MDA-MB-231 cells 
with α-ENaC overexpression and Aldosterone (10nM) to control. Mean ±SEM. Analysed using 
a two-way ANOVA with Tukey’s post hoc test. No statistically significant differences were 
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observed between α-ENaC overexpression and control or aldosterone (10nM) and control. 
N=6, n=6.  
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Figure 3.11: The migration of BT-549 cells, in scratch assays, showed no difference with α-
ENaC overexpression or 10nM aldosterone, compared to the control. A) Control scratch area 
at time of scratch (0 Hour); B) Control scratch area at 12 hours after the scratch (12 Hours); C) 
α-ENaC overexpression scratch area at time of scratch (0 Hour); D) α-ENaC overexpression 
scratch area at 12 hours after the scratch (12 Hours); E) Aldosterone (10nM) scratch area at 
time of scratch (0 Hour); F) Aldosterone (10nM) scratch area at 12 hours after scratch (12 
Hours); G) Pooled results comparing the migratory ability of BT-549 cells with α-ENaC 
overexpression and Aldosterone (10nM) to control. Mean ±SEM. Analysed using a two-way 
ANOVA with Tukey’s post hoc test. No statistically significant differences were observed 




ENaC is a sodium ion channel that is found in many epithelia including the kidney, lung, colon, 
and mammary tissue (Boyd & Náray-Fejes-Tóth, 2007; Hanukoglu & Hanukoglu, 2016). ENaC 
is a heterotrimer consisting of either α-ENaC or δ-ENaC, β-ENaC, and γ-ENaC and plays an 
important role in the regulation of blood pressure (Hanukoglu & Hanukoglu, 2016; Noreng et 
al., 2018).  
The role of ENaC in regulating EMT has been suggested with preliminary data from the 
McDonald laboratory that reported higher mRNA levels of ENaC in epithelial-like breast cancer 
cell lines than mesenchymal-like breast cancer cell lines. This suggests that altering ENaC 
mRNA level may lead to cells acquiring different characteristics, such as becoming more 
migratory, which are important in the progression of cancer into a metastatic disease. ENaC 
has been previously reported to be involved in cell migration. A role for ENaC in cell migration 
has been shown in keratinocytes, vascular smooth muscle cells, D54-MG glioblastoma 
multiforme cells, and in BeWo choriocarcinoma cells (Grifoni et al., 2006; del Mónaco et al., 
2009; Kapoor et al., 2009; Yang et al., 2013). These studies show that altering ENaC expression 
effects cell migration and suggest that overexpressing or knocking down ENaC in breast cancer 
cells could alter cell migration. 
The mRNA levels of ENaC subunits has been correlated with breast cancer prognosis. As seen 
in (Figure 1.3), using a bioinformatics tool developed by Györffy et al, (2010), patients with 
higher expression of α-ENaC or δ-ENaC were correlated with having a better prognosis when 
compared to patients with lower expression of α-ENaC or δ-ENaC.   
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Breast cancer is an important disease worldwide as it is the most common and deadliest form 
of female cancer. This is reflected in New Zealand with a high age standardised incidence rate 
of 94.1 cases per 100,000 women in 2017 (Ministry of Health, 2019). An age standardised 
mortality rate of 17.3 deaths per 100,000 women was reported in 2016, with almost 700 
deaths (Ministry of Health, 2018). The majority of breast cancer deaths are due to metastases, 
therefore finding new treatments, especially those that can target metastatic disease, is an 
important direction for research. Due to their location on the cell membrane and their role in 
many cellular functions, ion channels such as ENaC may be an attractive potential target for 
treatment of diseases including breast cancer.  
This project aimed to understand the role of ENaC in breast cancer cell migration and build on 
the results of a previous honours project that used amiloride and aldosterone to alter ENaC 
activity and mRNA level. To investigate the role of ENaC in breast cancer cell migration in this 
project, two ENaC subunits, α-ENaC and δ-ENaC, were either overexpressed or knocked down. 
Scratch assays were used as a functional test of cell migration and qPCR was performed to 
confirm whether transfection resulted in a change in ENaC mRNA level. It was hypothesised 
that overexpression of α-ENaC or δ-ENaC will cause an increase in migration of mesenchymal 
breast cancer cells and knockdown of α-ENaC or δ-ENaC will cause a decrease in migration of 
mesenchymal breast cancer cells. 
4.1 The Effect of Overexpressing of α-ENaC or δ-ENaC in Scratch Assays  
Overexpression of α-ENaC or δ-ENaC was performed in two triple negative, mesenchymal 
breast cancer cell lines, MDA-MB-231 and BT-549. Cell migration was assessed using scratch 
assays with photographs taken at multiple time points. Area of the scratch was calculated as 
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a percentage of the original scratch area at time 0. In MDA-MB-231 cells, overexpression of α-
ENaC or δ-ENaC did not have an effect on migration compared to the control. In BT-549 cells, 
overexpression of α-ENaC or δ-ENaC did not have an effect on migration compared to the 
control. This contradicted my hypothesis that overexpression of α-ENaC or δ-ENaC in 
mesenchymal breast cancer cell lines would lead to an increase in breast cancer cell migration. 
This was not a result of unsuccessful transfection as qPCR showed a statistically significant 
increases in both α-ENaC and δ-ENaC mRNA in BT-549 cells and a statistically significant 
increase of δ-ENaC mRNA in MDA-MB-231 cells. α-ENaC overexpression was trending towards 
statistical significance with a P value of 0.09, which is likely due to the varying magnitude of 
the increase. 
4.2 The Effect of Knockdown of α-ENaC or δ-ENaC in Scratch Assays 
Knockdown of α-ENaC or δ-ENaC was also performed in two triple negative, mesenchymal 
breast cancer cell lines, MDA-MB-231 and BT-549. This was performed to observe whether 
reducing ENaC expression would result in a change in breast cancer cell migration and was 
compared with the overexpression results. In MDA-MB-231 cells, knockdown of α-ENaC or δ-
ENaC did not have an effect on migration, when compared to control. Furthermore, 
knockdown of α-ENaC or δ-ENaC in BT-549 cells did not have an effect on migration, compared 
to the control. This contradicted my hypothesis that knockdown of α-ENaC or δ-ENaC in 
mesenchymal breast cancer cell lines would lead to a decrease in breast cancer cell migration. 
These results are likely due to unsuccessful transfection as no statistically significant difference 
in mRNA levels were observed in the qPCR experiments of both cell lines between the α-ENaC 
knockdown and control, or the δ-ENaC knockdown and control. Interestingly there was a 
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statistically significant difference in migration between α-ENaC knocked down cells and δ-
ENaC knocked down cells in BT-549 cells. This suggests that δ-ENaC is more involved in breast 
cancer cell migration than α-ENaC. However, this could be due to biological variability as qPCR 
experiments showed unsuccessful knockdown of both α-ENaC and δ-ENaC. 
4.3 Aldosterone Scratch Assays 
This project was based on the results of a previous project that also investigated the role of 
ENaC in breast cancer cell migration (McQueen, 2018). In the previous project, 
pharmacological agents were utilised with amiloride used to inhibit ENaC and aldosterone to 
increase ENaC expression. Statistically significant differences in migration were reported when 
they were used with MDA-MB-231 and BT-549 cells in scratch assays.  With 10nM of 
aldosterone, MDA-MB-231 cells saw a statistically significant reduction in migration at 12 
hours after scratch when compared to control. In BT-549 cells treated with 10nM of 
aldosterone, a statistically significant increase in migration was observed at 12 hours after 
scratch, when compared to control. As the overexpression and knockdown of α-ENaC or δ-
ENaC showed no significant difference compared to the control, there was an attempt to 
reproduce the previously reported 10nM aldosterone results as a positive control, and was 
performed alongside α-ENaC overexpression and control. The results of the previous project 
could not be replicated in these experiments. In MDA-MB-231 cells, no statistically significant 
differences were observed between either the α-ENaC overexpression and the control or 
10nM of aldosterone and the control. The same result was seen in BT-549 cells as there was 
no statistically significant difference was observed between α-ENaC or 10nM aldosterone and 
control. As qPCR had not been performed due to time constraints, it is not known whether the 
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α-ENaC overexpression result was due to unsuccessful transfection. As previous experiments 
have shown successful α-ENaC overexpression using the same transfection protocol, it was 
assumed that it was successful in these experiments. The status of the aldosterone used in 
these experiment was tested after obtaining the results to determine whether it was able to 
increase ENaC activity. An Ussing chamber current measurement experiment was performed 
using mouse cortical collecting duct (mCCD) epithelial cells. These cells were incubated with 
either aldosterone or vehicle followed by ENaC current measurements. The aldosterone used 
in this experiment was not able to increase ENaC current compared to the control. Previously, 
this protocol showed a significant increase in ENaC current with aldosterone therefore 
suggesting that this particular tube of aldosterone was non-functional (Cheung, data not 
shown). This provides an explanation for why the aldosterone cell migration results of the 
previous project could not be replicated. 
4.4 Possible Explanations for the Lack of Effect of Changing ENaC mRNA levels on Cell 
Migration 
Possible explanations for why altering α-ENaC or δ-ENaC mRNA levels had no effect on breast 
cancer cell migration could be due to: 1) other targets of aldosterone, 2) the breast cancer cell 
lines used in this project were in a more proliferative transition state rather than migratory, 
and 3) the need for the other ENaC subunits.   
This project was based on results of a previous honours project that also investigated the role 
of ENaC in breast cancer cell migration. Results from that project showed that aldosterone was 
able to alter the migration of breast cancer cell line cells compared to a control (McQueen, 
2018). This project aimed to build on those results by specifically targeting α-ENaC and δ-ENaC 
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subunits. The results from this project however, suggest that altering mRNA levels of α-ENaC 
or δ-ENaC has no effect on breast cancer cell migration, therefore, other targets of aldosterone 
may be responsible for the previously observed changes in cell migration.  
Aldosterone has been shown to be involved in breast cancer cell migration mediated by the 
G-Protein estrogen receptor (GPER) (Rigiracciolo et al., 2016). Aldosterone is a 
mineralocorticoid hormone produced within the adrenal gland (Booth et al., 2002). It has a 
well characterised role in responding to low blood pressure conditions as part of the RAAS 
pathway (Booth et al., 2002). Within breast cancer cells, aldosterone binds to the MR which 
can interact with GPER, and mediate the interaction of GPER and epidermal growth factor 
receptor (EGFR) to initiate EGFR/extracellular signal-regulated kinases (ERK) signalling. This 
can result in the upregulation of the sodium hydrogen exchanger 1 (NHE1) (Rigiracciolo et al., 
2016). NHE1 is an exchanger that transports one sodium ion into the cell for one proton out 
of the cell, and has a role in pH regulation, sodium transport, cell volume regulation, and cell 
migration (Stock & Schwab, 2006; Parker et al., 2015). Involvement of NHE1 in breast cancer 
cell migration mediated by aldosterone has been demonstrated in SkBr3 breast cancer cells. 
SkBr3 cells had MR knocked down or transfected with control siRNA and were exposed to 
10pM of aldosterone or vehicle for 48 hours. Scratch assays were then performed to compare 
cell migration. SkBr3 cells with MR knocked down were not able to migrate in response to 
aldosterone. NHE1 was shown to be important in this process as inhibition of NHE1 with 
cariporide showed a similar inability to migrate in response to aldosterone. This suggest that 
an upregulation of NHE1 by aldosterone rather than of ENaC could be responsible for the 
increase in cell migration observed in the previous honours project. 
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Unpublished data from the McDonald Laboratory suggests that ENaC is involved in breast 
cancer cell proliferation. Using EdU cell proliferation assays, overexpression of α-ENaC was 
able to reduce the percentage of proliferating cells in the same breast cancer cell lines used in 
this project: MDA-MB-231 and BT-549. When α-ENaC was knocked down in these cell lines, an 
increase in the percentage of proliferating cells was observed. Using the same overexpression 
and knockdown transfection protocol used to study proliferation, the results of my project 
suggest that ENaC, specifically α-ENaC and δ-ENaC, have no role in breast cancer cell 
migration. While cell migration and proliferation are often linked, some studies show they can 
be independent of each other. Feng et al (2017), showed that while gonadotropin exposure 
was able to significantly increase migration of SKOV3 and HO8910 ovarian cancer cells, it did 
not increase cellular proliferation (Feng et al., 2017). Another study by Zhou et al (2017), 
showed that silencing Serpin Peptidase Inhibitor, clade A member 3 (SERPINA3) with siRNA led 
to a significant decrease in migration but with no change in proliferation of MMRU melanoma 
cells (Zhou et al., 2017). 
A review of EMT in cancer progression has stated that there are different hybrid states 
between the epithelial and mesenchymal states (Pastushenko & Blanpain, 2019). Cells in these 
hybrid states express markers of both epithelial and mesenchymal phenotypes. This can be 
seen with changes in the two isoforms of transcription factor Paried related homeobox 1 
(Prrx1). Overexpression of Prrx1a leads to a transition state that is closer to an epithelial 
phenotype, with higher E-cadherin levels and decreased invasion, and is associated with 
metastatic outgrowth in new tissue. Overexpression of Prrx1b leads to a transition state that 
is closer to a mesenchymal phenotype, with decreased E-cadherin levels and increased 
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invasiveness, and is associated with increased dissemination of tumour cells (Takano et al., 
2016). Another study demonstrated the existence of these hybrid transition states and their 
different functional capabilities (Pastushenko et al., 2018). Six subsets of hybrid phenotypes 
were identified when using a genetic mouse model of skin squamous cell carcinoma. These 
subsets were characterised based on the expression of three markers that were most 
frequently heterogeneously expressed during EMT: CD106, CD51, and CD61. These subsets 
displayed different functional characteristics with different subtypes becoming more invasive 
or more metastatic than others (Pastushenko et al., 2018). Hybrid transition states are also 
seen within breast cancer cells (Yu et al., 2013). Breast cancer tissue cells were analysed based 
the expression of several epithelial and mesenchymal markers. Many cells were observed to 
co-express markers of both epithelial and mesenchymal phenotypes with the proportion of 
cells expressing either an epithelial, mesenchymal, or hybrid phenotype able to change with 
response to treatment and disease progression (Yu et al., 2013). This demonstrates the 
existence of hybrid transition states and that these hybrid transition states may be functionally 
different from one another. This means that one transition state could have a migratory 
phenotype while another could be more proliferative (Figure 4.1). If the cell lines used in this 
project, MDA-MB-231 and BT-549, were derived from cells in a more proliferative hybrid state, 






Figure 4.1: Proposed mechanism of Epithelial to Mesenchymal Transition with functionally 
different hybrid transition states. Presents cells in an epithelial state or in two separate hybrid 
transition states: a migratory transition state and a proliferating transition state. 
ENaC is a heterotrimer consisting of an α-ENaC or δ-ENaC subunit, a β-ENaC subunit, and a γ-
ENaC subunit. Individual α-ENaC or δ-ENaC subunits are sufficient to produce an amiloride 
sensitive current, however when co-expressed with β-ENaC and γ-ENaC the amiloride sensitive 
current increased markedly (Canessa et al., 1994; McDonald et al., 1995; Waldmann et al., 
1995). In this project, changes in cell migration were only investigated with changes in 
expression of either α-ENaC or δ-ENaC subunits. However, before the initiation of this project, 
unpublished proliferation data from the McDonald laboratory suggested that there was no 
difference between α-ENaC and αβγ-ENaC on the effect on proliferation. Therefore, the use 
of single subunits of ENaC was thought to be sufficient to understand their role in breast cancer 
cell migration. The unpublished proliferation data also demonstrated that inhibition of ENaC 
produced a similar increase in the percentage of proliferating cells to the knockdown of ENaC 
subunits. This suggested that ENaC activity was important, and so α-ENaC or δ-ENaC, the two 
subunits that are sufficient to produce an amiloride sensitive current, were selected for this 
project. Cell migration may however be different to cell proliferation, so altering the 
expression of β-ENaC and γ-ENaC subunit in tandem with α-ENaC or δ-ENaC may help 
delineate the true role of ENaC in breast cancer cell migration.  
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4.5 Limitations and Next Steps 
4.5.1 Cell Passage Effects 
The passage number of the cells used in this project was at approximately passage number 60 
when scratch assay experiments began. Cell passage effects can alter transfection efficiency, 
protein expression, and diverge cells away from the original tissue from which it was derived 
(Mouriaux et al., 2016; American Type Culture Collection, 2019). In this project qPCR was used 
to validate the transfection of the cells. This works by comparing the level of mRNA within the 
cells and inferring a change in protein levels. Due to the use of high passage number cells, this 
may not be the case and so no functional changes would be observed (American Type Culture 
Collection, 2019). Follow up experiments should be performed with low passage number cells 
and include western blotting to validate a change in protein levels.  
4.5.2 Knockdown of α-ENaC and δ-ENaC  
The knockdown of α-ENaC or δ-ENaC was attempted using siRNA to observe what effect this 
may have on breast cancer cell migration. The results from the scratch assays performed in 
this project showed that knockdown of α-ENaC or δ-ENaC had no effect on cell migration 
compared to the control in MDA-MB-231 and BT-549 mesenchymal breast cancer cells. This 
however could be due to unsuccessful transfection or non-functional siRNA as results from the 
qPCR experiments showed no significant difference in mRNA level of either α-ENaC or δ-ENaC 
when compared to the control. The knockdown experiments should be repeated using new 
components to elucidate the true effect that knockdown of α-ENaC or δ-ENaC has on breast 
cancer cell migration. 
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4.5.3 Positive Controls 
To ensure the scratch assays are functioning correctly, positive controls should be utilised. 
Other publications have used a variety of positive controls including 10% FBS, if serum free 
media is used, and Allantoin (Bullard et al., 2018; Muniandy et al., 2018). Phalliodin conjugated 
with a fluorescent marker could be used as a pseudo marker for cell migration. This would 
allow for the visualisation of the F-actin cytoskeleton to determine whether it displays 
morphological features that would be expected within migrating cells such as lamellipodium 
protrusions (Schwab, 2001). Functional assays such as Ussing chamber current measurements 
could not be performed with these cells as do not form an epithelium. Follow up projects 
should be performed with a positive control.   
4.5.4 Serum Media 
The scratch assays were performed in media containing 10% FBS to match the conditions used 
by the previous honours project. This decision was made as the cells used were not reaching 
confluence in serum free media. It is unlikely however, that proliferation had a large effect in 
reducing the size of the scratch area as the doubling time of the breast cancer cell lines used 
in this project was reported in publications as at least 25 hours (Fonagy et al., 1994; Limame 
et al., 2012). Follow up projects using scratch assays could use serum free media to arrest the 
cell cycle or add inhibitors of proliferation such as Mitomycin C and Cytosine β-d-
arabinofuranoside hydrochloride to remove any effect of proliferation (Giretti et al., 2014; 
Vang Mouritzen & Jenssen, 2018). Monitoring levels of proliferation markers such as Ki-67 may 
also be useful to determine whether there is any contribution of proliferation to the results 




4.5.5 Technical Difficulties with qPCR and Scratch Assays 
Due to the high sensitivity of qPCR, special care had to be taken when performing these 
experiments. Contamination of primers and other components early in the project meant that 
validation of overexpression and knockdown experiments was delayed. New components had 
to be ordered and these were aliquoted to reduce further contamination. A specific area and 
lab coat was used for qPCR with ethanol sprayed on all surfaces to reduce contamination. 
Loading of the qPCR plate was completed on ice to ensure the cDNA was not degraded. When 
loading cDNA into the wells, special care was taken to ensure the pipette tip was not carried 
over wells which did not contain the same cDNA to avoid contamination.  
Keeping the size of the scratch area consistent was another task that required special care. 
Although these results were normalised by taking a percentage of the original scratch area, 
comparing a large initial scratch area with a smaller initial scratch area would confound the 
results. Another way of analysing the data could be to calculate the rate of cell migration with 
live-cell microscopy, which could reduce the confounding effect of the initial size of the scratch 
area (Jonkman et al., 2014; Bobadilla et al., 2019).  
4.5.6 Alternative Cell Migration Assays 
Only one migration assay, the scratch assay, was used in this project. Employing the use of 
another migration assay could either corroborate or contradict the results in this project. Cell 
exclusion zone assays are another migration assay which use similar rationale to the scratch 
assays. This assay uses a cell seeding stopper to occlude a region on the plate from cell growth. 
The cells can be seeded around the stopper, and when confluence is reached, the stopper can 
be removed to begin the experiment (Hulkower & Herber, 2011). This has some advantages 
over the scratch assays used in this project as no cells are damaged to produce the area that 
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is uncovered by cells and the size of the uncovered area is less variable compared to the 
scratch assays (Hulkower & Herber, 2011).  
Boyden chamber assays are also another migration assay that could be used (Justus et al., 
2014). This assay uses transwells with an insert with a porous filter membrane. Serum free 
media is added to the insert and serum containing media is added to the bottom well. This 
provides a chemotactic gradient for cells to migrate towards. Cells are seeded onto the insert 
and can migrate through the porous filter membrane, toward the chemo-attractant. The 
amount of cells able to migrate into the bottom well can be quantified and compared with 
different experimental conditions. This can also be used as an invasion assay with Matrigel 
simulating the extracellular matrix. A layer of Matrigel is added over the filter membrane 
before the cells are seeded. The amount of cells able to reach the bottom well can be 
quantified and represents the invasive capability of the cells (Justus et al., 2014).  
4.5.7 Future Directions 
Due to time constraints the effect of overexpressing or knocking down α-ENaC and δ-ENaC on 
EMT marker expression could not be explored. As ENaC has been shown to be differentially 
expressed within epithelial and mesenchymal breast cancer cell lines, investigating whether 
overexpression or knockdown of ENaC could possible induce EMT or MET would be an 
interesting direction of research. This can be explored by performing qPCR with primers for E-
cadherin, an epithelial marker, and Vimentin and N-cadherin, two mesenchymal markers. 
As knockdown of α-ENaC and δ-ENaC was not successful in this project, producing cell lines 
with a stable knockdown of α-ENaC and δ-ENaC subunits may be another option. This can be 
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achieved using viral vectors and shRNA. The shRNA can be integrated into the DNA, and induce 
stable knockdown through RNA interference activity (Moore et al., 2010).  
While ENaC may not have a role in breast cancer cell migration, it may still be involved in other 
aspects of breast cancer, such as cellular invasion. Alterations to cellular invasion with changes 
to ENaC can be investigated using the Boyden chamber assay described in Section 4.5.6.  
Investigating whether ENaC is involved in cell morphology may be another aspect that could 
be investigated. A study by Yang et al, observed that co-culturing breast cancer MCF-7 and 
MDA-MB-231 cells with different subsets of macrophages led to changes in cellular 
morphology (Yang et al., 2016). A ratio of mid-point diameter and cell perimeter was used as 
a way to quantify cell morphology with a higher ratio associated with an epithelial phenotype 
while a lower ratio with a mesenchymal phenotype. They found that co-culturing MCF-7 
epithelial breast cancer cells with M2 macrophages promoted a mesenchymal phenotype as 
the mid-point diameter-cell perimeter ratio decreased compared to control and co-culturing 
with M0 or M1 macrophages (Yang et al., 2016). A similar effect was seen in MDA-MB-231 
mesenchymal breast cancer cells as co-culturing with M2 macrophages decreased the mid-
point diameter-cell perimeter ratio while co-culturing with M1 macrophages increased the 
ratio, compared to control and co-culturing with M0 macrophages (Yang et al., 2016). This 
suggested that M1 macrophages promote an epithelial phenotype while M2 macrophages 
promote a mesenchymal phenotype (Yang et al., 2016). Investigating whether altering ENaC 




The aim of this project was to investigate whether ENaC has a role in breast cancer cell 
migration. To do this the expression of two ENaC subunits, α-ENaC and δ-ENaC, were 
overexpressed in two mesenchymal breast cancer cell lines. It was hypothesised that 
overexpression of α-ENaC or δ-ENaC will cause an increase in the migration of mesenchymal 
breast cancer cells. The results of this project contradict the hypotheses as no significant 
difference in cell migration was observed when α-ENaC or δ-ENaC was overexpressed in two 
mesenchymal breast cancer cell lines. As knockdown of α-ENaC and δ-ENaC was not 
successful, the hypothesis that knockdown of α-ENaC of δ-ENaC will cause a decrease in the 
migration of mesenchymal breast cancer cells could not be confirmed or denied. This project 
did have its limitations and follow up experiments should be performed with these being 
addressed to observe whether there is a change in breast cancer cell migration. ENaC has been 
shown to be involved in proliferation of breast cancer cells and so could also be involved in 
other aspects of breast cancer metastases. Investigating a possible role of ENaC in invasion 
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6.1 RNA Extraction Protocol 





6.2 PCR Result Sheets 
Within the Content Row: 
 GAPDH = GAPDH Primers 
 A/α-ENaC = α ENaC Primers 
 D/δ-ENaC = δ ENaC Primers 
Within the Sample Row: 
 Date scratch assay cells were lysed 
 MD = MDA-MB-231 Cells 
 BT = BT-549 Cells 
 OE = Overexpression Transfection with Plasmid DNA 
 KD = Knockdown Transfection with siRNA 
 C/C1/C2 = Control Experiments 
 A/A1/A2 = α ENaC Experiments 
 D/D1/D2 = δ ENaC Experiments 
 WATER = Water Control 
 -RT CTRL = Minus Reverse Transcriptase Enzyme Control 





MD A&D OE (3-8-19); MD-BT A&D OE (13-8-19); MD-BT KD (17-8-19) α-ENaC PCR PLATE 
 





BT A&D OE (22-7-19); MD A&D OE (8-7-19); BT A&D OE (26-7-19)  α-ENaC PCR PLATE 
 










MD A&D OE (17-6-19) PCR PLATE 
 
 
 
